Skip to main content

Table 6 Multivariate analysis of predictors of progression-free and overall survival

From: Baseline total metabolic tumor volume combined with international peripheral T-cell lymphoma project may improve prognostic stratification for patients with peripheral T-cell lymphoma (PTCL)

Variable Progression-free survival Overall survival
B SE Wald HR (95% CI) P value* B SE Wald HR (95% CI) P value*
LDH level, normal/elevate 0.472 0.233
B symptoms, no/yes 0.233 0.469
ECOG PS, 0–1/ ≥ 2 0.708 0.988
BMB, negative/positive 0.932 0.999
Platelet cell count, ≥ 150 × 109/L 0.276 0.289
IPI, 0–2/3–5 0.888 0.827
PIT, 0–1/2–4 0.825 0.632
IPTCLP, 0–1/2, 3 0.947 0.310 9.351 2.577 (1.405–4.727) 0.002 0.859 0.310 7.664 2.360 (1.285–4.336) 0.006
SUVmax, low/high 0.689 0.688
TMTV, low/high 1.629 0.348 21.953 5.096 (2.579–10.072) < 0.001 1.536 0.346 19.766 4.647 (2.361–9.148) < 0.001
TLG, low/high 0.964 0.933
  1. Univariate analyses of factors predictive of survival in patients whose scans were evaluated using TMTV and TLG
  2. CI confidence interval, SE standard error, CI confidence interval, HR hazards ratio, LDH lactate dehydrogenase, ECOG PS Eastern Cooperative Oncology Group performance status, BMB bone marrow biopsy, IPI International Prognostic Index, PIT prognostic index for T-cell lymphoma, IPTCLP International peripheral T cell lymphoma Project, TMTV total metabolic tumor volume, TLG total lesion glycolysis
  3. *P < 0.05